Search research articles
Contact Us
Filters
Showing results (151-160 of 338) with videos related to
Page
of 34
Sort By:
Journal for Immunotherapy of Cancer
|
July 15, 2020
Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective
Casey Quinn, Louis P Garrison, Anja K Pownell, et al.
European Urology
|
September 17, 2020
Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma
Sumanta K Pal, Bernard J Escudier, Michael B Atkins, et al.
BJU International
|
March 17, 2010
Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy
Toni K Choueiri, Meredith M Regan, Jonathan E Rosenberg, et al.
Cancer Research
|
April 19, 2005
Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion
Arnold H Zea, Paulo C Rodriguez, Michael B Atkins, et al.
Developmental Cell
|
May 8, 2019
YAP/TAZ Inhibition Induces Metabolic and Signaling Rewiring Resulting in Targetable Vulnerabilities in NF2-Deficient Tumor Cells
Shannon M White, Maria Laura Avantaggiati, Ivan Nemazanyy, et al.
Journal for Immunotherapy of Cancer
|
December 19, 2019
Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection
Neil J Shah, Ghassan Al-Shbool, Matthew Blackburn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2015
Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study
Michael B Atkins, Gwenaelle Gravis, Kazimierz Drosik, et al.
Cancer
|
June 11, 2015
Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma
M Dror Michaelson, Rana R McKay, Lillian Werner, et al.
Cancer
|
September 16, 2008
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study
Michael B Atkins, Jeffrey A Sosman, Sanjiv Agarwala, et al.
Translational Oncology
|
April 8, 2014
The role of angiopoietins as potential therapeutic targets in renal cell carcinoma
Xiaoen Wang, Andrea J Bullock, Liang Zhang, et al.
Page
of 34
Search research articles
Search
Showing results (151-160 of 338) with videos related to
Sort By:
Page
of 34
Journal for Immunotherapy of Cancer
|
July 15, 2020
Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective
Casey Quinn, Louis P Garrison, Anja K Pownell, et al.
European Urology
|
September 17, 2020
Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma
Sumanta K Pal, Bernard J Escudier, Michael B Atkins, et al.
BJU International
|
March 17, 2010
Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy
Toni K Choueiri, Meredith M Regan, Jonathan E Rosenberg, et al.
Cancer Research
|
April 19, 2005
Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion
Arnold H Zea, Paulo C Rodriguez, Michael B Atkins, et al.
Developmental Cell
|
May 8, 2019
YAP/TAZ Inhibition Induces Metabolic and Signaling Rewiring Resulting in Targetable Vulnerabilities in NF2-Deficient Tumor Cells
Shannon M White, Maria Laura Avantaggiati, Ivan Nemazanyy, et al.
Journal for Immunotherapy of Cancer
|
December 19, 2019
Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection
Neil J Shah, Ghassan Al-Shbool, Matthew Blackburn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2015
Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study
Michael B Atkins, Gwenaelle Gravis, Kazimierz Drosik, et al.
Cancer
|
June 11, 2015
Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma
M Dror Michaelson, Rana R McKay, Lillian Werner, et al.
Cancer
|
September 16, 2008
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study
Michael B Atkins, Jeffrey A Sosman, Sanjiv Agarwala, et al.
Translational Oncology
|
April 8, 2014
The role of angiopoietins as potential therapeutic targets in renal cell carcinoma
Xiaoen Wang, Andrea J Bullock, Liang Zhang, et al.
Page
of 34